Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. Go to Publication You Might Also Like Hydroxychloroquine for COVID-19: What is our Current State of Knowledge? September 3, 2020 Primary immune deficiency in the intensive care unit: It is never too late to diagnose and treat. July 15, 2011 Nomenclature of drug-resistant tuberculosis. November 11, 2013 MDR, XDR, TDR tuberculosis: ominous progression. April 23, 2012 Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. March 6, 2016
Primary immune deficiency in the intensive care unit: It is never too late to diagnose and treat. July 15, 2011
Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. March 6, 2016